HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update
- Wednesday, February 1, 2023, 7:12
- PR Newswire
- Add a comment
Full-Year 2022 net revenue of KRW 110 billion, up 8% over 2021 reaching a record high Strong R&D momentum to continue with batoclimab entering multiple pivotal studies with the first Phase 3 data readout in China expected in 2023 Top-line data from tanfanercept’s Phase 3 dry eye study…
About the Author
admin has written 21716 stories on this site.